Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
about
Molecular characterization of WDCP, a novel fusion partner for the anaplastic lymphoma tyrosine kinase ALKAnaplastic lymphoma kinase: signalling in development and diseaseThe role of the ALK receptor in cancer biologyMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsEmerging importance of ALK in neuroblastomaMolecular pathogenesis of peripheral neuroblastic tumorsALK and NSCLC: Targeted therapy with ALK inhibitorsTargeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic HypogonadismAnaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cellsGenome-wide association study of the child behavior checklist dysregulation profileEffect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L miceALK-rearrangements and testing methods in non-small cell lung cancer: a reviewSynthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinibAn evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol.The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning.ALK-activating homologous mutations in LTK induce cellular transformation.Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancerPleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Anaplastic Lymphoma Kinase Acts in the Drosophila Mushroom Body to Negatively Regulate Sleep.The novel object recognition memory: neurobiology, test procedure, and its modifications.ALK-immunoreactive neoplasms.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerCrizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyAdopting ALK and LTK.Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactionsALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.Deletion of Frs2alpha from the ureteric epithelium causes renal hypoplasiaAnaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Anaplastic lymphoma kinase as a therapeutic target.The heparin-binding growth factor midkine: the biological activities and candidate receptors.Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.ALK-positive cancer: still a growing entity.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
P2860
Q24308008-60B7EA52-497C-44DF-A745-F20E81DA9D1FQ24312329-66600DC0-183C-4B31-9CA8-0E008CD45305Q26738384-6A51E573-2CF6-452B-9082-C9F53BE1AACDQ26769659-52982139-B27B-4FD0-9ED1-0D4D9F148612Q26858819-5F77F609-BED4-4A98-B989-BBC1F656E278Q28271405-DCC0B2D7-AB03-4DEC-9E3E-1F65A26344E2Q28393324-62B7B12A-F53D-49D4-97E3-81AC1E864661Q28547121-1C13F868-B468-45C2-959C-52200EDEAC58Q28571575-609A7AAE-6B1A-4240-A0C7-841A59C36315Q28943428-7A012A56-A112-458A-8BF4-F92BB6A91A87Q33487136-28531AA5-33E7-4D87-AB26-34955C99593DQ33757085-371CA461-60FF-4A7B-93B5-319E99260942Q33776835-3C98588A-58EF-4878-91D4-2B9342F6CD43Q33804619-ACB6D813-2D71-4ED8-ABF3-2433FD95DBE6Q33974947-A259D4FE-4B17-4B0E-9FE4-3CEB80B5A59DQ34031191-74906872-0DF4-4330-A539-3D9F7448657CQ34162940-0774D7BB-06D8-494E-9FEF-6EAC1B9DD9DBQ34619273-BAECD7E8-56C4-49D5-9D48-1C72E1FA6694Q34869224-2717A503-0802-4363-AE57-C57689F4CEC7Q35080328-15C05B69-AB6D-4807-87AC-B91199D56C6EQ35832009-8159DD83-2720-4203-9111-3B93AE73B91DQ35904451-6692FF82-867F-4E96-B4FE-437F932505B8Q36092957-E397D648-DE9C-4E03-A28D-F599A89EA551Q36096398-1FFFF1EE-6325-45E2-8D63-FAC8CF278321Q36405628-1CF908CF-85B1-4A95-A6C6-8F40A6D453FBQ36435102-CCBC98F7-4FD7-4794-8170-94D93B19E199Q36435120-AB4368D7-A08A-4039-957A-5ED0F49A99C9Q36477122-392B1EB0-FCD3-4A62-AA6C-1446769749A6Q36524188-2879B36C-56BF-47AD-B61E-5C0A53C5F5B3Q37003600-D6726757-158D-4769-94B2-67C4C6C6FADBQ37411178-47D0329D-C5CB-4FAC-9940-B2230E7A49BBQ37430764-634AE6C1-EAA9-454F-866B-F1A7D096B66BQ37592115-1340E7DF-7D25-4003-B665-503B654829F9Q37940719-FF3919F3-964C-433E-8782-A0E2DE3BFE3FQ38045455-F5CBCD98-7923-4D34-9785-86BFF0072563Q38102670-ABA183A1-7B3C-408A-AA50-D4466FB39D92Q38148969-0C113015-BFD6-4212-AC23-EEAC0C34D128Q38184584-7CE12BC2-12C5-4E24-98C2-52657F8EED06Q38484053-E8601980-AE19-494E-A3E4-FF3F935C5404Q38623421-D6790396-AA5E-4297-9F3A-CD47062854EA
P2860
Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
description
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im Februar 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/02/01)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/02/01)
@nl
наукова стаття, опублікована в лютому 2008
@uk
مقالة علمية (نشرت في فبراير 2008)
@ar
name
Behavioral and neurochemical a ...... al for psychiatric indications
@ast
Behavioral and neurochemical a ...... al for psychiatric indications
@en
Behavioral and neurochemical a ...... al for psychiatric indications
@nl
type
label
Behavioral and neurochemical a ...... al for psychiatric indications
@ast
Behavioral and neurochemical a ...... al for psychiatric indications
@en
Behavioral and neurochemical a ...... al for psychiatric indications
@nl
prefLabel
Behavioral and neurochemical a ...... al for psychiatric indications
@ast
Behavioral and neurochemical a ...... al for psychiatric indications
@en
Behavioral and neurochemical a ...... al for psychiatric indications
@nl
P2093
P2860
P3181
P356
P1476
Behavioral and neurochemical a ...... al for psychiatric indications
@en
P2093
Alan Wheeldon
Andrew Mead
George McAllister
Ignacio Munoz-Sanjuan
James G. Bilsland
Kerry A. Waters
Matthew Thakur
Paul Whiting
Petr Znamenskiy
Robert Heavens
P2860
P2888
P304
P3181
P356
10.1038/SJ.NPP.1301446
P407
P577
2008-02-01T00:00:00Z
P5875
P6179
1027120481